-
Norepinephrine bitartrate: Assay Reliability
2026-09-11
A scenario-driven guide to using (-)-Norepinephrine (+)-bitartrate (SKU C8723) in cell viability, proliferation, and cardiovascular research workflows. It connects receptor pharmacology, solution handling, assay controls, and renal vascular evidence to more interpretable experimental results.
-
Oltipraz: From Nrf2 Signals to Assay Meaning
2026-09-10
Oltipraz is a dithiolethione Nrf2 activator used to study phase II detoxification, redox defense, and carcinogen detoxification. This article interprets recent MASLD evidence as an assay-design framework while separating pathway engagement from claims about ferroptosis or chemoprevention.
-
Lipo3K Transfection Reagent for APOL1 Studies
2026-09-10
Build APOL1 isoform, variant, and APOL3 interaction assays with a low-toxicity lipid transfection reagent designed for plasmids, siRNA, mRNA, and difficult cell models. This workflow emphasizes controlled expression, DNA and siRNA co-transfection, serum-compatible optimization, and readouts that distinguish delivery effects from APOL1-driven cell injury.
-
Lipid Peroxidation (MDA) Assay Kit for Ferroptosis
2026-09-09
Use the Lipid Peroxidation (MDA) Assay Kit to connect biochemical lipid damage with ferroptosis and oxidative-stress phenotypes in doxorubicin injury models. Its dual absorbance and fluorescence readouts support flexible measurements across tissue, cell lysate, plasma, serum, and urine while complementary assays establish mechanism.
-
Bicinchoninic Acid Assay: K4102 Practical Guide
2026-09-09
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 supports sensitive total-protein measurement in dilute biochemical samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research and sample normalization, not diagnostic, clinical, or medical testing.
-
Lysosomal β-Galactosidase Staining Kit in HNSCC
2026-09-08
Explore how the Lysosomal β-Galactosidase Staining Kit can strengthen senescence studies in cisplatin-resistant HNSCC. This article distinguishes lysosomal enzyme activity from senescence-specific conclusions and translates SLC25A1 mechanism into better assay decisions.
-
LCN2 and Ferroptosis in Sepsis-Associated AKI
2026-09-08
The reference study identifies Lipocalin-2 (LCN2) as a potential driver of renal ferroptosis in sepsis-associated acute kidney injury through suppression of the AMPK/SIRT3/FOXO3a antioxidant axis. Its combination of genetic perturbation, pathway rescue, and complementary mouse and HK-2 cell models provides a mechanistic framework for interpreting oxidative injury and lipid peroxidation in SA-AKI.
-
Deracoxib Workflows for COX-2 and Cancer Assays
2026-09-07
Build more informative inflammation and canine cancer experiments with Deracoxib, a selective COX-2 inhibitor suited to dose-response, apoptosis, and cell-cycle workflows. This guide connects practical solvent handling and assay optimization with evidence from canine mammary tumor research, while distinguishing exploratory in vitro concentrations from clinically relevant exposure.
-
L-NAME Hydrochloride: From NO Biology to Translation
2026-09-07
A translational framework for using L-NAME Hydrochloride and NG-nitro-L-arginine methyl ester to connect NOS inhibition with vascular physiology, inflammatory signaling, and more rigorous disease-model interpretation.
-
ATP Solution (100 mM): Reliable mRNA Assays
2026-09-05
Learn how ATP Solution (100 mM), SKU K1043, can standardize ATP-dependent transcription, kinase, ligation, and phosphorylation workflows that support cell viability and p21 mRNA–LNP research. The article translates product specifications into practical guidance for handling, controls, interpretation, and vendor selection.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-09-04
2-Hydroxypropyl-β-cyclodextrin is a water-compatible cyclic oligosaccharide used to screen the apparent aqueous solubility of poorly soluble hydrophobic compounds, especially molecules containing aromatic or phenyl groups. It is appropriate for excipient and biochemical solubility workflows, but complexation, stability, bioavailability, and biological performance require assay-specific validation.
-
LAG-3–TCR Proximity in T-Cell Suppression
2026-09-04
A 2025 Cell study shows that LAG-3-mediated inhibition depends not simply on MHC class II binding, but on spatial proximity between LAG-3 and the T cell receptor (TCR). Its mechanistic and therapeutic experiments connect this proximity to CD3ε/Lck disruption and demonstrate that an Fc-attenuated LAG-3/TCR bispecific antibody can suppress pathogenic T-cell activity in autoimmune models.
-
Dextromethorphan Hydrobromide for Neuroprotection
2026-09-03
Build reproducible excitotoxicity and ion-channel assays with Dextromethorphan hydrobromide, an NMDA receptor antagonist suited to mechanistic neuroprotection research. This guide combines formulation, dose-response design, electrophysiology, cerebral ischemia model planning, and troubleshooting while clearly separating established product specifications from workflow recommendations.
-
Acifran: Practical HCAR Signaling Workflows
2026-09-03
Use Acifran to connect HCAR2/HCAR3 receptor pharmacology with cAMP and lipid metabolism experiments. This workflow emphasizes paired-receptor comparisons, structure-informed assay design, reproducible dosing, and troubleshooting rather than relying on a single downstream lipid endpoint.
-
Protease Inhibitor Cocktail for TCR Signaling Assays
2026-09-02
Learn how a Protease Inhibitor Cocktail EDTA-Free can preserve native TCR–LAG-3 complexes, phosphorylation states, and protein interactions during immunology workflows. This guide translates a recent mechanistic study into practical sample-preparation decisions for Western blotting, co-immunoprecipitation, and kinase assays.